SpringWorks Therapeutics (SWTX)
(Delayed Data from NSDQ)
$41.71 USD
+0.78 (1.91%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $41.73 +0.02 (0.05%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum D VGM
Brokerage Reports
0 items in cart
SpringWorks Therapeutics [SWTX]
Reports for Purchase
Showing records 21 - 40 ( 198 total )
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Further Revising OGSIVEO Forecasts Upward; Raising PT to $73
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Nirogacestat Receives FDA Approval For Desmoid Tumors; Raising PT to $64
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for SWTX 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Mirdametinib Delivers; Nirogacestat FDA Decision Looms; Lowering PT to $52
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Mirdametinib Working To Spring Onto the Market
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Nirogacestat Imminent FDA Decision; 3Q23 Financials; Lowering PT to $58
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Biotechnology- 2023 Small Molecule Precision Oncology Review and Outlook
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Nirogacestat Approval Still Likely in Our View, Despite FDA Letter; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Multiple Catalysts by Year-End; 2Q23 Financial Results; Lowering PT to $66
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Biotechnology- EHA 2023 Roundup for Covered Companies (Part 2)
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Nirogacestat Approval Decision Delayed; Updates From ASCO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R